ChemoCentryx Inc (NASDAQ:CCXI) CEO Thomas J. Schall sold 7,275 shares of the stock in a transaction on Monday, January 7th. The shares were sold at an average price of $12.04, for a total transaction of $87,591.00. Following the transaction, the chief executive officer now directly owns 2,236,130 shares in the company, valued at approximately $26,923,005.20. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Shares of ChemoCentryx stock opened at $12.38 on Friday. The firm has a market capitalization of $600.24 million, a price-to-earnings ratio of 34.39 and a beta of 1.38. ChemoCentryx Inc has a 12-month low of $8.01 and a 12-month high of $15.08. The company has a debt-to-equity ratio of 0.69, a quick ratio of 2.87 and a current ratio of 2.87.
ChemoCentryx (NASDAQ:CCXI) last announced its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.03. The business had revenue of $8.98 million for the quarter, compared to analyst estimates of $11.55 million. ChemoCentryx had a net margin of 13.88% and a return on equity of 32.16%. Research analysts expect that ChemoCentryx Inc will post -0.83 earnings per share for the current fiscal year.
A number of institutional investors have recently made changes to their positions in CCXI. Sei Investments Co. grew its holdings in ChemoCentryx by 203.5% in the 2nd quarter. Sei Investments Co. now owns 8,549 shares of the biopharmaceutical company’s stock worth $113,000 after acquiring an additional 5,732 shares during the last quarter. Macquarie Group Ltd. purchased a new stake in shares of ChemoCentryx in the 2nd quarter worth about $130,000. grace capital purchased a new stake in shares of ChemoCentryx in the 2nd quarter worth about $132,000. Paloma Partners Management Co purchased a new stake in shares of ChemoCentryx in the 2nd quarter worth about $159,000. Finally, MetLife Investment Advisors LLC lifted its position in shares of ChemoCentryx by 55.2% in the 3rd quarter. MetLife Investment Advisors LLC now owns 19,233 shares of the biopharmaceutical company’s stock worth $243,000 after purchasing an additional 6,841 shares during the period. 53.83% of the stock is currently owned by institutional investors and hedge funds.
Several equities analysts recently commented on CCXI shares. BidaskClub raised shares of ChemoCentryx from a “hold” rating to a “buy” rating in a report on Tuesday, September 25th. ValuEngine raised shares of ChemoCentryx from a “buy” rating to a “strong-buy” rating in a report on Tuesday, December 25th. B. Riley started coverage on shares of ChemoCentryx in a report on Tuesday. They set a “neutral” rating and a $12.50 target price on the stock. Zacks Investment Research raised shares of ChemoCentryx from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a report on Wednesday. Finally, Canaccord Genuity increased their target price on shares of ChemoCentryx from $18.00 to $20.00 and gave the company a “buy” rating in a report on Monday, November 12th. Three research analysts have rated the stock with a hold rating, three have issued a buy rating and three have issued a strong buy rating to the company. ChemoCentryx presently has an average rating of “Buy” and a consensus price target of $16.42.
ChemoCentryx Company Profile
ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV).
Read More: What is a blue-chip stock?
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.